The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells

Journal of Neuro-Oncology

Volumn 100, Issue 1, 2010, Pages 51-64

  Yoshida, D ^a   Koketshu, K ^a   Nomura, R ^a   Teramoto, A ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

AMD3100; CXCL12; CXCR4; Growth hormone; Pituitary adenoma

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; COMPLEMENTARY DNA; CXCL2 CHEMOKINE; GROWTH HORMONE; INHIBIN; MESSENGER RNA; OXYGEN; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1ALPHA;

ANIMAL CELL; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; DNA MICROARRAY; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE SILENCING; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; HYPOPHYSIS CELL; HYPOPHYSIS FUNCTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL BLOCKING; PROLACTINOMA; RAT; SIGNAL TRANSDUCTION; TISSUE LEVEL; TISSUE MICROARRAY; UPREGULATION; WILD TYPE;

ADENOMA; ANIMALS; BETA CAROTENE; CELL HYPOXIA; CELL LINE, TUMOR; CHEMOKINE CXCL12; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE; HETEROCYCLIC COMPOUNDS; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PITUITARY NEOPLASMS; RATS; RECEPTORS, CXCR4; RNA, MESSENGER; RNA, SMALL INTERFERING; STATISTICS AS TOPIC;

EID: 79952188680     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0152-6     Document Type: Article

References (45)

1. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT (2009) Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 9(4):442-458
2. Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107(6):1053-1062
3. Galanis A, Karapetsas A, Sandaltzopoulos R (2009) Metal-induced carcinogenesis, oxidative stress and hypoxia signalling. Mutat Res 674(1-2):31-35
4. Jensen RL (2009) Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92(3):317-335
5. Hendriksen EM, Span PN, Schuuring J et al (2009) Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvasc Res 77(2):96-103
6. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H (2002) Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 46(10):2587-2597 (Pubitemid 36118921)
7. De Falco E, Porcelli D, Torella AR et al (2004) SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 104(12):3472-3482 (Pubitemid 39564415)
8. Simcock JW, Penington AJ, Morrison WA, Thompson EW, Mitchell GM (2009) Endothelial precursor cells home to a vascularized tissue engineering chamber by application of the angiogenic chemokine CXCL12. Tissue Eng Part A 15(3):655-664
9. Li JK, Yu L, Shen Y, Zhou LS, Wang YC, Zhang JH (2008) Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol 14(15):2308-2313 (Pubitemid 351877599)
10. Matsuo Y, Ochi N, Sawai H et al (2009) CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer 124(4):853-861
11. Takabatake Y, Sugiyama T, Kohara H, Matsusaka T, Kurihara H, Koni PA, Nagasawa Y, Hamano T, Matsui I, Kawada N, Imai E, Nagasawa T, Rakugi H, Isaka Y (2009) The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. J Am Soc Nephrol 20(8):1659-1961. doi:10.1681/ASN.2008060640
12. Ueland J, Yuan A, Marlier A, Gallagher AR, Karihaloo A (2009) A novel role for the chemokine receptor CXCR4 in kidney morphogenesis: an in vitro study. Dev Dyn 238(5):1083-1091
13. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H (2008) Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 99(3):539-542 (Pubitemid 351228571)
14. Barbero S, Bajetto A, Bonavia R et al (2002) Expression of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 in human brain tumors and their involvement in glial proliferation in vitro. Ann N Y Acad Sci 973:60-69 (Pubitemid 36124978)
15. Bian XW, Yang SX, Chen JH et al (2007) Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 61(3):570-578
16. Han Y, Wang J, He T, Ransohoff RM (2001) TNF-alpha down-regulates CXCR4 expression in primary murine astrocytes. Brain Res 888(1):1-10 (Pubitemid 32056257)
17. Barbieri F, Bajetto A, Porcile C, Pattarozzi A, Schettini G, Florio T (2007) Role of stromal cell-derived factor 1 (SDF1/CXCL12) in regulating anterior pituitary function. J Mol Endocrinol 38(3):383-389 (Pubitemid 46723254)
18. Barbieri F, Bajetto A, Stumm R et al (2008) Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin Cancer Res 14(16):5022-5032
19. Florio T, Casagrande S, Diana F et al (2006) Chemokine stromal cell-derived factor 1alpha induces proliferation and growth hormone release in GH4C1 rat pituitary adenoma cell line through multiple intracellular signals. Mol Pharmacol 69(2):539-546 (Pubitemid 43121951)
20. Lee Y, Kim JM, Lee EJ (2008) Functional expression of CXCR4 in somatotrophs: CXCL12 activates GH gene, GH production and secretion, and cellular proliferation. J Endocrinol 199(2):191-199
21. Nomura R, Yoshida D, Teramoto A (2009) Stromal cell-derived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia. J Neurooncol 94(2):173-181
22. Ceradini DJ, Gurtner GC (2005) Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 15(2):57-63 (Pubitemid 40693388)
23. Schioppa T, Uranchimeg B, Saccani A et al (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198(9):1391-1402 (Pubitemid 37392484)
24. Zagzag D, Lukyanov Y, Lan L et al (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86(12):1221-1232 (Pubitemid 44789912)
25. Yoshida D, Nomura R, Teramoto A (2009) Signaling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1alpha, in AtT20 mouse ACTH-secreting pituitary adenoma cells. J Neuroendocrinol 21(5):481-488
26. Jacobson O, Weiss ID, Szajek L, Farber JM, Kiesewetter DO (2009) 64Cu-AMD3100 - a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem 17(4):1486-1493
27. Carro E, Senaris RM, Mallo F, Dieguez C (1998) Inhibin suppresses in vivo growth hormone secretion. Neuroendocrinology 68(5):293-296 (Pubitemid 28526306)
28. Lu B, Xu J, Chen J, Yu J, Xu E, Lai M (2008) TaqMan low density array is roughly right for gene expression quantification in colorectal cancer. Clin Chim Acta 389(1-2):146-151
29. Yamada S, Takada K (2003) Angiogenesis in pituitary adenomas. Microsc Res Tech 60(2):236-243 (Pubitemid 36125712)
30. Gorczyca W, Hardy J (1987) Arterial supply of the human anterior pituitary gland. Neurosurgery 20(3):369-378 (Pubitemid 17040466)
31. Kristof RA, Aliashkevich AF, Hans V et al (2003) The regional oxygen saturation of pituitary adenomas is lower than that of the pituitary gland: microspectrophotometric study with potential clinical implications. Neurosurgery 53(4):880-885
32. Cosio G, Jeziorski MC, Lopez-Barrera F, De La Escalera GM, Clapp C (2003) Hypoxia inhibits expression of prolactin and secretion of cathepsin-D by the GH4C1 pituitary adenoma cell line. Lab Invest 83(11):1627-1636 (Pubitemid 37421103)
33. 125I] stromal cell-derived factor-1alpha binding to CXCR4 receptors in rat brain and human neuroblastoma cells. J Neuroimmunol 110(1-2):151-160
34. Bajetto A, Bonavia R, Barbero S et al (1999) Glial and neuronal cells express functional chemokine receptor CXCR4 and its natural ligand stromal cell-derived factor 1. J Neurochem 73(6):2348-2357
35. Reis FM, Luisi S, Carneiro MM et al (2004) Activin, inhibin and the human breast. Mol Cell Endocrinol 225(1-2):77-82 (Pubitemid 39297057)
36. Bilezikjian LM, Blount AL, Leal AM, Donaldson CJ, Fischer WH, Vale WW (2004) Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin. Mol Cell Endocrinol 225(1-2):29-36 (Pubitemid 39297052)
37. Carro E, Senaris RM, Mallo F, Dieguez C (1999) Regulation of hypothalamic somatostatin and growth hormone releasing hormone mRNA levels by inhibin. Brain Res Mol Brain Res 66(1-2):191-194 (Pubitemid 29148349)
38. Flomenberg N, DiPersio J, Calandra G (2005) Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol 114(4):198-205 (Pubitemid 41567002)
39. Donzella GA, Schols D, Lin SW et al (1998) AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4(1):72-77 (Pubitemid 28133082)
40. Lenoir M, Djerdjouri B, Perianin A (2004) Stroma cell-derived factor 1alpha mediates desensitization of human neutrophil respiratory burst in synovial fluid from rheumatoid arthritic patients. J Immunol 172(11):7136-7143 (Pubitemid 38669157)
41. De Clercq E (2005) Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem 5(9):805-824
42. Azab AK, Runnels JM, Pitsillides C et al (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113(18):4341-4351
43. Redjal N, Chan JA, Segal RA, Kung AL (2006) CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 15(22):6765-6771 (Pubitemid 44876846)
44. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100(23):13513-13518 (Pubitemid 37444773)
45. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N (2009) AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 75(5):1240-1247